Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HaemoneticsSTU:HAZ -2.78%32 Forward PE Ratio is 15.90 as of Aug. 07, 2026. GuruFocus rates STU:HAZ with a GF Score™ of 32/100 and a GF Value™ of €69.88 (Fairly Valued). The stock has 5 warning signs investors should review. Among 391 Medical Devices & Instruments companies, Haemonetics ranks better than 61.64% on this metric.
Haemonetics's Forward PE Ratio for today is 15.90.
Haemonetics (STU:HAZ) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Haemonetics Forward PE Ratio Related Terms
Haemonetics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Haemonetics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haemonetics Forward PE Ratio Chart
Haemonetics Annual Data
Trend
2018-03
2019-03
2020-03
2021-03
2022-03
2023-03
2024-03
2025-03
2026-03
Forward PE Ratio
35.46
31.55
25.91
33.33
34.36
23.58
18.35
12.27
10.40
Haemonetics Quarterly Data
2017-09
2017-12
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
2026-06
Forward PE Ratio
26.53
32.57
35.46
40.82
54.95
31.06
31.55
40.65
43.10
31.25
25.91
32.26
30.40
36.36
33.33
23.75
24.10
20.20
34.36
22.52
26.32
24.15
23.58
23.26
25.58
20.41
18.35
17.79
16.39
14.97
12.27
14.48
9.75
14.16
10.40
15.01
STU:HAZ vs IRTC, ITGR, LIVN: Forward PE Ratio Comparison
For the Medical Devices subindustry, Haemonetics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haemonetics Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Haemonetics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Haemonetics (STU:HAZ) has a Forward PE Ratio of 15.90 as of Aug. 07, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Haemonetics and its competitors. According to the industry distribution chart, Haemonetics ranks #150 out of 391 companies in the Medical Devices & Instruments industry, placing it in the top 38.4%.
Is Haemonetics' Forward PE Ratio too high?
Haemonetics' current Forward PE Ratio is 15.90. The Medical Devices & Instruments industry median Forward PE Ratio is 20.08. Haemonetics' value of 15.90 is 20.8% below this industry median. Based on the distribution chart, Haemonetics ranks #150 out of 391 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Haemonetics has a GF Score™ of 32/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Forward PE Ratio compare to IRTC and ITGR?
According to the Medical Devices & Instruments industry distribution chart, Haemonetics ranks #150 out of 391 companies for Forward PE Ratio. This puts Haemonetics in the upper half of its industry. The industry median Forward PE Ratio is 20.08. Haemonetics' value of 15.90 is 20.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 20.08, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haemonetics's current Forward PE Ratio of 15.90 is 20.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Haemonetics and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 20.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haemonetics's current Forward PE Ratio is 15.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Based on GuruFocus' analysis, Haemonetics (STU:HAZ) is currently considered Fairly Valued. The stock's GF Value™ is €69.88, compared to a current price of €70.00 — trading 0.2% above its estimated fair value. The current Forward PE Ratio is 15.90 and 20.8% below the Medical Devices & Instruments industry median of 20.08. Haemonetics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Forward PE Ratio is 15.90 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haemonetics (STU:HAZ) Overvalued in 2026?
Based on GuruFocus' analysis, Haemonetics stock appears to be overvalued.
The current stock price of €70.00 is trading 0.2% above its estimated GF Value™ of €69.88.
GuruFocus considers Haemonetics to be Fairly Valued.
Key valuation signals for STU:HAZ:
Forward PE Ratio: 15.90
GF Value™: €69.88 vs. price of €70.00 (0.2% above fair value)
Industry Position: 20.8% below the Medical Devices & Instruments median (#150 of 391)
No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
32GF Score
Get the complete analysis for STU:HAZ
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:HAZ has been successfully added to your 
